Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation. Issue 7 (11th May 2019)
- Record Type:
- Journal Article
- Title:
- Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation. Issue 7 (11th May 2019)
- Main Title:
- Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation
- Authors:
- Berends, Sophie E.
D'Haens, Geert R. A. M.
Schaap, Tiny
de Vries, Annick
Rispens, Theo
Bloem, Karien
Mathôt, Ron A. A. - Abstract:
- Abstract : Aims: Therapeutic drug monitoring (TDM) can optimize the efficacy of infliximab (IFX) in patients with inflammatory bowel disease (IBD). Because of the delay between blood samples taken at trough and availability of results, dose adjustments can only be carried out at the next infusion, typically 8 weeks later. Dried blood samples (DBS) performed at home to measure IFX concentrations can reduce the time to adapt dose/dosing interval. Here, we aimed to validate the clinical application of DBS for IFX in IBD patients and to evaluate the feasibility of home sampling. Methods: DBS results from 40 IBD patients on IFX treatment were compared to serum sample results at trough, peak, and 3–5 weeks after IFX infusion. Subsequently, patients performed DBS home sampling one week before the next IFX infusion. These were compared to serum concentrations as predicted by Bayesian analysis. Results: IFX concentrations from finger prick and venous puncture correlate well. DBS IFX concentrations showed high correlation with serum IFX concentrations (Spearman correlation: ≥0.965), without bias. Passing‐Bablok regression for IFX concentrations in DBS from home sampling also showed no bias (intercept: 1.02 mg L −1 (95% CI −1.77–2.04 mg L −1 ), slope: 0.82 (95% CI 0.63–1.40)), with reasonable correlation (Spearman correlation: 0.671). Conclusions: Timely adjustment of IFX dose/dosing interval can be facilitated by IFX concentration measurement in home‐sampled DBS. DBS is a reliableAbstract : Aims: Therapeutic drug monitoring (TDM) can optimize the efficacy of infliximab (IFX) in patients with inflammatory bowel disease (IBD). Because of the delay between blood samples taken at trough and availability of results, dose adjustments can only be carried out at the next infusion, typically 8 weeks later. Dried blood samples (DBS) performed at home to measure IFX concentrations can reduce the time to adapt dose/dosing interval. Here, we aimed to validate the clinical application of DBS for IFX in IBD patients and to evaluate the feasibility of home sampling. Methods: DBS results from 40 IBD patients on IFX treatment were compared to serum sample results at trough, peak, and 3–5 weeks after IFX infusion. Subsequently, patients performed DBS home sampling one week before the next IFX infusion. These were compared to serum concentrations as predicted by Bayesian analysis. Results: IFX concentrations from finger prick and venous puncture correlate well. DBS IFX concentrations showed high correlation with serum IFX concentrations (Spearman correlation: ≥0.965), without bias. Passing‐Bablok regression for IFX concentrations in DBS from home sampling also showed no bias (intercept: 1.02 mg L −1 (95% CI −1.77–2.04 mg L −1 ), slope: 0.82 (95% CI 0.63–1.40)), with reasonable correlation (Spearman correlation: 0.671). Conclusions: Timely adjustment of IFX dose/dosing interval can be facilitated by IFX concentration measurement in home‐sampled DBS. DBS is a reliable method to measure IFX and can be used to predict IFX trough concentrations. … (more)
- Is Part Of:
- British journal of clinical pharmacology. Volume 85:Issue 7(2019)
- Journal:
- British journal of clinical pharmacology
- Issue:
- Volume 85:Issue 7(2019)
- Issue Display:
- Volume 85, Issue 7 (2019)
- Year:
- 2019
- Volume:
- 85
- Issue:
- 7
- Issue Sort Value:
- 2019-0085-0007-0000
- Page Start:
- 1544
- Page End:
- 1551
- Publication Date:
- 2019-05-11
- Subjects:
- biologicals -- clinical pharmacology -- gastroenterology -- immunology -- therapeutic drug monitoring
Pharmacology -- Periodicals
Drugs -- Periodicals
615.1 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2125 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/bcp.13939 ↗
- Languages:
- English
- ISSNs:
- 0306-5251
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 2307.180000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 15225.xml